The hypotensive peptide adrenomedullin (AM) is assumed to act as a factor inhibitory on elevation of blood pressure and on progression of the hypertensive organ damage, and plasma AM levels are elevated in patients with hypertension. The aim of the present study is to explore whether or not a rise in plasma AM levels precedes the development of hypertension. Normotensive local residents without apparent cardiovascular or renal disease (n ¼ 177) were divided into low and high AM groups based on the median concentration of AM in plasma (11.9 fmol/ml), and followed up for 3 years for development of hypertension. The incidence of hypertension was higher in the residents with high AM than low AM levels (27.8 vs 11.5%, Po0.01), whereas a similar analysis of plasma levels of atrial or brain natriuretic peptides revealed no such difference. The plasma AM level was found to be a significant parameter for the development of hypertension in a univariate analysis (Po0.01), but not in a multivariate analysis. Meanwhile, the plasma AM level was significantly (Po0.01) correlated with age and body mass index (BMI), two variables independently significant for the development of hypertension. The present findings suggest that an elevation of the plasma AM level associated with aging and increased BMI precedes the development of hypertension in the normotensive subjects.
Introduction
Adrenomedullin (AM) is a blood pressure-lowering peptide expressed in the cardiovascular tissues including the vascular wall and heart. [1] [2] [3] Plasma levels of AM are elevated in patients with hypertension, heart failure or arteriosclerosis, as compared with control subjects. [4] [5] [6] Results of genetic manipulation and prolonged low-dose infusion suggest that AM functions to suppress rises in blood pressure or the progression of hypertensive organ damage via its protective effects on cardiovascular tissues. 2, 3, [7] [8] [9] Both atrial and brain natriuretic peptides (ANP and BNP) are cardiac hormones with cardiovascular effects similar to AM including natriuresis, diuresis and vasodilatation. 10 Plasma levels of ANP and BNP are also higher in patients with hypertension or heart failure than in controls. 5, 10, 11 The secretion of ANP and BNP is augmented by preload or afterload to the heart; 10, 11 whereas, according to the results of cell culture and animal studies, the secretion of AM from the cardiovascular tissues is enhanced by such factors as angiotensin II, endothelin-1, aldosterone, interleukin-1b and tumour necrosis factor-a (TNF-a), that are involved in the progression of cardiovascular damage. 2, 3 In patients with hypertension, a close correlation between the plasma level of AM and hypertensive organ damage was found, and in those with atherosclerotic vascular diseases, increased plasma AM levels were associated with the severity of the disease. 4, 6 Based on these findings, we speculate that minimal or preclinical damage of the cardiovascular system, which precedes an elevation of blood pressure, can be detected by measuring plasma AM levels. Our hypothesis in this study is that a rise in plasma AM levels precedes the development of hypertension in normotensive subjects. To test this hypothesis, we examined the relationship between plasma AM levels and the development of hypertension in normotensive, local residents with no apparent cardiovascular disease. In addition, similar analyses were performed for plasma levels of ANP and BNP.
Materials and methods
Study subjects and protocol Local residents having an annual health checkup in the Kiyotake area, Miyazaki, Japan, were examined in this study. The subjects enrolled were normotensive with systolic blood pressure (SBP) of o140 mm Hg and diastolic blood pressure (DBP) of o90 mm Hg and were not taking any antihypertensive medicine. They were determined to have no overt cardiovascular diseases such as ischaemic heart disease, congestive heart failure and atherosclerotic vascular disease based on their medical history and physical examination. Those who had diabetes mellitus were excluded from the study. Blood pressure was measured with a sphygmomanometer in a sitting position by experienced nurses, and then blood was drawn from an antecubital vein. To measure the plasma concentrations of AM, ANP and BNP, blood was collected into tubes with 1.0 mg/ml of EDTA-2Na and 500 kallikrein inhibitory units (KIU)/ml of aprotinin. Plasma was obtained by centrifugation at 3000 r.p.m. for 10 min at 41C and stored at À401C until assayed. The subjects were followed up annually for 3 years with a regular checkup for the development of hypertension defined as SBPX140 mm Hg or DBPX90 mm Hg. This study was approved by the Review Committee of Cooperative and Commissioned Research of the University of Miyazaki, and all subjects gave written informed consent to participate.
Assay procedures
The plasma AM, ANP and BNP concentrations were measured with specific immunoradiometric assays (ShionoRIA AM, ANP and BNP kits, Shionogi & Co., Ltd. Osaka, Japan), detailed methods of which have been described previously. 12 The coefficients of variation (CV) for these measurements are as follows (intra-and inter-assay CVs): AM, 7.3 and 9.0; ANP, 7.1 and 5.7; BNP, 5.7 and 9.9%.
Statistical analysis
All the data were analysed with SPSS software version 13.0 (SPSS Inc., Chicago, IL, USA). Comparisons of two groups were assessed with unpaired ttest or w 2 test and correlations between two variables with simple regression analysis. The development of hypertension during the follow-up period was evaluated using the Kaplan-Meier method and longrank test. The data were further examined by a univariate regression analysis, and then, a multivariate regression model was used to extract significant, independent factors for development of hypertension. All the data were expressed as the mean7s.d. and a P-value less than 0.05 was considered to be significant.
Results
The means for plasma levels of AM, ANP and BNP were 12.272.6, 5.2772.75 and 4.6274.29, with medians of 11.9, 4.74 and 3.52 fmol/ml, respectively, in the normotensive residents. The subjects were divided into two groups based on the median concentration of AM in plasma (Table 1 ). Figure 1 shows the development of hypertension during the follow-up period of 3 years. As shown in Figure 1a , the rate of hypertension was significantly higher in the high AM than low AM group (27.8 vs 11.5%, Po0.01). We carried out similar analyses based on high and low levels of ANP or BNP, but found no significant differences in the rates (Figure 1b and c) . Table 2 shows the results of univariate and multivariate regression analyses of relationship between the development of hypertension and the other parameters. As shown, the age, body mass index (BMI), SBP, DBP, triglyceride level and plasma AM level were extracted as significant parameters by the univariate analysis. A comparison of basal characteristics between the low and high AM groups (Table 1 ) revealed significant differences in the age, BMI, serum creatinine, triglyceride, and though not significant, slightly higher male ratio, SBP and DBP in the high AM group. Accordingly, we further analysed the development of hypertension using a multivariate regression model with all the parameters shown in Table 1 . As a result, the age and BMI were identified as independently significant factors in the development of hypertension (Table 2) . Meanwhile in linear regression analyses, the baseline plasma AM level was found to be significantly (Po0.01) correlated with the age (r ¼ 0.261) and BMI (r ¼ 0.238).
Discussion
Plasma levels of AM are elevated in patients with hypertension, heart failure, acute myocardial infarction and atherosclerotic vascular diseases, with a close relationship between the plasma level and the severity of the disease. [4] [5] [6] Moreover, higher plasma AM levels are associated with a poorer prognosis in patients with heart failure and acute myocardial infarction. 13, 14 These findings suggest a close correlation between the plasma AM level and damage to the cardiovascular system. In the present study, the higher the plasma AM level was, the higher the elevation in blood pressure among the normotensive subjects who had no overt cardiovascular diseases. The plasma AM level was revealed to be a significant parameter by the univariate, but not by the multivariate analysis, and this should have come from the intimate relationships between the plasma level and the age or BMI, two variables independently significant in the multivariate analysis. Although the follow-up period was short and the sample size was relatively small to precisely determine the incidence of hypertension, the present findings suggest that plasma AM levels elevated in association with aging and increased BMI precedes elevation of blood pressure.
The reason for the higher rate of hypertension in the high AM group remains unclear. In patients with hypertension, the plasma AM level has been shown to progressively rise in proportion to the severity of hypertensive organ damage, [4] [5] [6] although the mechanism behind the rise is not fully understood. It was reported that plasma AM levels were closely related to renal function partly because of the reduced clearance of the peptide. 4 Indeed, a simple regression analysis revealed significant correlation between the plasma AM and serum creatinine levels in the present study (data not shown). However, the creatinine levels of the study subjects were at 1.0 mg/dl or lower and found to be insignificant for development of hypertension by the univariate and multivariate analyses. In cell culture and animal experiments, various factors have been shown to stimulate AM production in the heart or blood vessels, namely angiotensin II, aldosterone, endothelin-1, interleulin-1b, TNF-a, and oxidative stress. 2, 3 Additionally, the mechanical stretch of cardiac myocytes and shear stress applied to cultured endothelial cells were shown to modulate the production of AM in vitro and in vivo.
2,3 These factors, both humoral and mechanical, are assumed to contribute to the increased level of AM in plasma of patients with hypertension or heart failure, and similar mechanisms may be considered for the normotensive subjects with high levels of plasma AM.
Consistent with our previous report, 15 the baseline plasma AM level was significantly correlated with the age and BMI in the present study. The mechanism for age-related increase in plasma AM levels remained to be clarified, whereas it should be noted that Letizia et al. 16 reported elevated plasma AM levels in obese subjects, which are possibly associated with hyperinsulinaemia. Recently, AM was shown to be expressed and secreted from adipose tissue, 17 and the AM expression in cultured 3T3-L1 adipocytes was augmented by TNF-a, a factor secreted from adipocytes. 18 Thus, increased secretion from adipose tissue should also be taken into account in the normotensive subjects with high levels of plasma AM, although further studies are necessary to identify the source of AM in plasma. In contrast to AM, higher BMI has recently shown to be associated with lower plasma BNP in the general population as well as in patients with heart failure;
19,20 however, we found no significant correlations with r 2 values less than 0.002 between the plasma levels of ANP or BNP and BMI in the present study. This could partly be attributed to the small number of obese subjects in the present study, in comparison with the previous reports:
19,20 only 1.1% of our subjects were obese with BMI larger than 30 kg/m 2 . Possessing hypotensive property similar to that of AM, both ANP and BNP are assumed to act against retention of fluid volume and elevation of blood pressure. 10 It has been reported that the plasma BNP level is a prognosticator in patients with chronic heart failure or acute myocardial infarction. 21, 22 Similar to increased plasma AM levels, higher plasma BNP levels are associated with a poorer prognosis in such cases. 21, 22 According to a recently published community-based study, higher plasma levels of BNP and of an N-terminal fragment of ANP are significantly associated with higher rates of death and cardiovascular morbidity. 23 Meanwhile in the present study, neither ANP nor BNP levels were significantly related to a rise in blood pressure. Because the plasma level of ANP or BNP rises in response to preload or afterload to the heart, it seems reasonable that we found no correlation between the development of hypertension and the plasma levels among the subjects without hypertension or any sign of heart disease.
In summary, the present findings suggest that the plasma AM level is elevated prior to the development of clinically overt hypertension, in association with aging and increased BMI, in the normotensive subjects. Given its hypotensive and cardiovascular protective actions, AM may function to suppress elevations of blood pressure not only in hypertensive patients but also in subjects without clinically overt hypertension.
